Navigation Links
Vermillion Reports Financial Results for the Third Quarter 2010
Date:11/11/2010

shares outstanding were 10.3 million and 6.4 million for the nine months ended September 30, 2010 and 2009, respectively.

About VermillionVermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health.  Additional information about Vermillion can be found on the Web at www.vermillion.com.

About OVA1™OVA1™ is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers -- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), beta 2-Microglobulin (beta 2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) -- and a proprietary FDA-cleared software device to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned. OVA1™ is a trademark of Vermillion, Inc.  Additional information about OVA1™ can be found on the Web at www.ova-1.com.

Forward-Looking StatementCertain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of f
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Vermillion Receives Award From the Society of Gynecologic Oncologists
2. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
3. Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder
4. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
5. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
6. Vermillion Presents Critical Data From Its OVA1 Clinical Trial
7. Vermillion Announces the Reappointment of Officers and Confirmation of Director
8. Vermillion to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
9. Vermillion Announces $43.05 Million Private Placement of Common Stock
10. Vermillion Files Plan of Reorganization
11. Vermillion Files Amended Plan of Reorganization and Exchanges Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 RenovoRx ( www.renovorx.com ) ... "Top Startup" Award at TiEcon 2013, the world,s largest ... team and quality of entrepreneurial ideas. RenovoRx was honored ... Santa Clara Convention Center. ... of the most enterprising startup companies across five verticals: ...
(Date:5/21/2013)... 2013 /PRNewswire-iReach/ -- The 2013 Pharma ChemOutsourcing Show slated ... greatest number of "Emerging" small molecule biotech company ... Alexay .  "No one saw this coming", ... show,s still 4 months away and we may end ... big surprise and great news for attendees". Thecurrent list ...
(Date:5/21/2013)... 21, 2013  IsoRay, Inc. (AMEX: ISR ... entered into an exclusive international distribution agreement with IASIS ... in Greece . IsoRay is a ... medical radioisotope applications for brain cancer, lung cancer, head ... IASIS Medical is ideally suited to ...
Breaking Medicine Technology:RenovoRx Named Winner of 2013 TiE50 "Top Startup" 2Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show 2IsoRay Announces A New International Distributor For Greece 2IsoRay Announces A New International Distributor For Greece 3
... PALO ALTO, Calif.--(BUSINESS WIRE)--Apr 12, 2007 - ... from its Phase,2 clinical trial of Hematide(TM) ... week at the National Kidney Foundation (NKF),2007 ... trial in patients previously treated with,three-times weekly ...
... 2007--The costs of eradicating,poliomyelitis from the remaining infected ... lower than the long term costs of trying,to ... vaccine is almost three times more effective against,type ... are,the findings of two Articles published Online and ...
Cached Medicine Technology:Affymax Announces Results From Phase 2 Clinical Trial of Hematide,for the Treatment of Anemia in Dialysis Patients 2Affymax Announces Results From Phase 2 Clinical Trial of Hematide,for the Treatment of Anemia in Dialysis Patients 3Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 2Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 3
(Date:5/21/2013)... Octo Consulting Group, an award-winning ... solutions to the Federal marketplace, has named Tracy ... the newly created role, Denny will be responsible ... firm’s business development function to include business development ... leading strategies to achieve the firm’s strategic growth ...
(Date:5/21/2013)... News) -- Aggressive treatment for prostate cancer may ... underlying medical conditions, a new study finds. ... and radioactive seed implants, can cause serious side ... bowel problems, explained researchers from the University of ... that older patients with slower growing forms of ...
(Date:5/21/2013)... A study of veterans at high risk for developing ... be highly effective in helping clinicians spot tiny lung ... indicate the earliest stages of the disease. LDCT uses ... conventional CT scan. , Results of the study will ... "Lung cancer is the leading cause of cancer-related death ...
(Date:5/21/2013)... In adults with chronic kidney disease (CKD), ... CKD progression and transplant failure. Now, a first-of-its-kind study ... University has found a possible similar effect in children ... , The study of 366 children aged 1 ... effect of secondhand smoke exposure in CKD, according to ...
(Date:5/21/2013)... , , TUESDAY, May 21 (HealthDay News) -- Finding early ... but a new study adds to a growing body ... may help spot the beginnings of disease in high-risk ... risk for lung cancer, 6 percent were found to ... biopsies to confirm the diagnosis. CT scans detect abnormalities ...
Breaking Medicine News(10 mins):Health News:Octo Consulting Group Appoints Tracy Denny as Vice President of Business Development 2Health News:Age, Other Illnesses May Make Prostate Cancer Treatment Unnecessary 2Health News:Low radiation scans help identify cancer in earliest stages 2Health News:Low radiation scans help identify cancer in earliest stages 3Health News:Exposure to Secondhand Smoke May Lead to Worsening of Pediatric Kidney Disease; Pediatric Nephrology Publishes Dayton Children’s, Johns Hopkins Joint Study 2Health News:Exposure to Secondhand Smoke May Lead to Worsening of Pediatric Kidney Disease; Pediatric Nephrology Publishes Dayton Children’s, Johns Hopkins Joint Study 3Health News:Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer 2Health News:Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer 3
... a senior citizen,s health, yet fewer than half of all seniors ... medical attention are far less likely to engage in any of ... their medications or getting a cane or walker that might ... UCLA Center for Health Policy Research. In the ...
... was true for males tying the knot with younger females, study ... men seven to nine years their junior could be upping their ... with a significantly younger guy raises a woman,s risk of death ... 12 issue of Demography . , Not that marrying much ...
... ... records between doctors is the latest expansion of the affiliation between The Mount Sinai Medical ... and most comprehensive ear, nose, and throat, allergy and audiology practice in the tri-state area. ... New York, NY (Vocus) ...
... Scientists at The Wistar Institute offer a new explanation for ... the reasons why melanoma remains the deadliest form of skin ... explain why melanoma cells behave like both conventional tumor cells ... May 14 issue of the journal Cell thatcontrary ...
... held promise for building new organs to replace damaged livers, ... is getting cells grown in a lab dish to form ... MIT-Harvard Division of Health Sciences and Technology (HST) have come ... encapsulating living cells in cubes and arranging them into 3-D ...
... will continue validating its ToxCast screening tool by ... GlaxoSmithKline, Sanofi-Aventis, and Merck. These drugs never entered ... levels of toxicity when the pharmaceutical companies conducted ... Food and Drug Administration as part of the ...
Cached Medicine News:Health News:Falls and follow-ups: Medical attention following a fall critical to senior health 2Health News:Women Who Marry Younger Men May Die Earlier 2Health News:Mount Sinai Medical Center and ENT & Allergy Associates, LLP Create First-Of-Its-Kind Physician Portal 2Health News:Mount Sinai Medical Center and ENT & Allergy Associates, LLP Create First-Of-Its-Kind Physician Portal 3Health News:Wistar scientists explain the persistence of melanoma through 'dynamic stemness' 2Health News:Wistar scientists explain the persistence of melanoma through 'dynamic stemness' 3Health News:Tissue engineers create a new way to assemble artificial tissues 2Health News:Tissue engineers create a new way to assemble artificial tissues 3Health News:Pharmaceutical companies provide EPA 100 drugs to help predict toxicity 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: